Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

The new J-code will become effective in January and will provide reimbursement when Exparel is used in the office setting and for office-based surgeries.

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...

The regimen has shown promise in preventing graft-versus-host disease in patients who received a haploidentical stem cell ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

The results come from a phase IIa safety and tolerability study. The drug’s developers say they are working with regulatory ...

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...

The IQVIA analysis finds that the impact of drug price negotiation on patients’ out-of-pocket spending could also be smaller ...

Studies measuring patient preference stacked up in subcutaneous administration’s favor, according to a recently published ...